Floeter Mary K, Traynor Bryan J, Farren Jennifer, Braun Laura E, Tierney Michael, Wiggs Edythe A, Wu Tianxia
From the National Institute of Neurological Disorders and Stroke (M.K.F., J.F., L.E.B., M.T., E.A.W., T.W.) and National Institute of Aging (B.J.T.), NIH, Bethesda, MD.
Neurology. 2017 Jul 18;89(3):234-241. doi: 10.1212/WNL.0000000000004115. Epub 2017 Jun 14.
To assess changes in 3 clinical measures, the Revised ALS Functional Rating Scale (ALSFRS-R), letter fluency, and Frontal Behavioral Inventory (FBI), over time in mutation carriers (C9+) with varied clinical phenotypes.
Thirty-four unrelated participants with mutations in were enrolled in a prospective natural history study. Participants were classified as asymptomatic, amyotrophic lateral sclerosis (ALS), ALS-familial frontotemporal dementia (FTD), or behavioral-variant FTD by clinical diagnostic criteria. Diagnostic cognitive and motor tests were repeated at 6 and 18 months. The ALSFRS-R, letter fluency, and FBI were administered at baseline and follow-up visits at 6, 12, and 18 months.
The clinical diagnosis of most patients did not change over the follow-up. ALSFRS-R scores correlated with measures of motor function. Letter fluency correlated with FBI and cognitive tests. ALSFRS-R, letter fluency, and FBI differed among the C9+ diagnostic subgroups at enrollment and worsened over follow-up in symptomatic patients, with different slopes among the subgroups. Most patients survived to the 6-month time point after enrollment. Survival of C9+ patients with ALS and C9+ patients with ALS-FTD declined over the 12- and 18-month follow-up.
The pattern of scores of the ALSFRS-R, letter fluency, and FBI distinguished between ALS, ALS-FTD, and FTD presentations of mutation carriers and asymptomatic carriers. Longitudinal changes in these measures occurred with disease progression in a manner consistent with presenting phenotype.
评估携带不同临床表型的突变携带者(C9+)在一段时间内,3项临床指标(修订版肌萎缩侧索硬化功能评定量表(ALSFRS-R)、字母流畅性和额叶行为量表(FBI))的变化情况。
34名携带 突变的非亲属参与者被纳入一项前瞻性自然史研究。根据临床诊断标准,参与者被分类为无症状、肌萎缩侧索硬化(ALS)、ALS-家族性额颞叶痴呆(FTD)或行为变异型FTD。在6个月和18个月时重复进行诊断性认知和运动测试。在基线以及6、12和18个月的随访时进行ALSFRS-R、字母流畅性和FBI测试。
大多数患者的临床诊断在随访期间没有变化。ALSFRS-R评分与运动功能指标相关。字母流畅性与FBI和认知测试相关。在入组时,C9+诊断亚组之间的ALSFRS-R、字母流畅性和FBI存在差异,并且在有症状的患者中,随访期间病情恶化,亚组之间的斜率不同。大多数患者在入组后存活至6个月时间点。在12个月和18个月的随访中,患有ALS的C9+患者和患有ALS-FTD的C9+患者的存活率下降。
ALSFRS-R、字母流畅性和FBI的评分模式区分了携带 突变的ALS、ALS-FTD和FTD患者以及无症状携带者的表现。这些指标的纵向变化随着疾病进展而发生,其方式与呈现的表型一致。